{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:50:52Z","timestamp":1760575852843,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T00:00:00Z","timestamp":1570233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jfma.2019.10.003","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T09:25:08Z","timestamp":1572254708000},"page":"712-719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Resistance-associated substitution and ledipasvir\/sofosbuvir therapy in Mongolian chronic hepatitis C patients"],"prefix":"10.1016","volume":"119","author":[{"given":"Shih-Jer","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhee","family":"Enkhzaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-Chung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulgaa","family":"Khosbayar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Hsueh","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-San","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damba","family":"Enkhtuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dogsom","family":"Ivshinkhorol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nyamsuren","family":"Naranzul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badarch","family":"Jargalsaikhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jazag","family":"Amarsanaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oidov","family":"Baatarkhuu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2019.10.003_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2019.10.003_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jfma.2015.06.012","article-title":"Hepatitis C virus infection in Taiwan: past, present, and future","volume":"115","author":"Kao","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2019.10.003_bib3","series-title":"Proceedings from the 24th annual meeting of the Korean Association for the Study of the Liver; June 14-June 16, 2018; Incheon, South Korea","article-title":"Disease burden of chronic hepatitis C virus infection in Mongolia: potential impact of attaining World Health Organization (WHO) 2030 goals","author":"Baatarkhuu","year":"2018"},{"key":"10.1016\/j.jfma.2019.10.003_bib4","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/j.1478-3231.2008.01820.x","article-title":"Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia: a population-based nationwide study","volume":"28","author":"Baatarkhuu","year":"2008","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2019.10.003_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5005\/jp-journals-10018-1260","article-title":"Epidemiology, genotype distribution, prognosis, control, and management of viral hepatitis B, C, D, and hepatocellular carcinoma in Mongolia","volume":"8","author":"Baatarkhuu","year":"2018","journal-title":"Euroasian J Hepato-Gastroenterol"},{"key":"10.1016\/j.jfma.2019.10.003_bib6","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S2468-1253(18)30243-7","article-title":"The public health challenge of liver cancer in Mongolia","volume":"3","author":"Znaor","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2019.10.003_bib7","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.10.003_bib8","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.10.003_bib9","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.10.003_bib10","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","article-title":"Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response","volume":"151","author":"Terrault","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2019.10.003_bib11","article-title":"Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: real-world data","author":"Hong","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jfma.2019.10.003_bib12","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2019.10.003_bib13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hep.29408","article-title":"Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease","volume":"69","author":"Backus","year":"2019","journal-title":"Hepatology"},{"year":"2019","series-title":"Ministry of Health, Mongolia. Report on Healthy Liver Program","key":"10.1016\/j.jfma.2019.10.003_bib14"},{"key":"10.1016\/j.jfma.2019.10.003_bib15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3851\/IMP3117","article-title":"Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients","volume":"22","author":"Backus","year":"2017","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jfma.2019.10.003_bib16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2019.10.003_bib17","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2019.10.003_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2019.10.003_bib19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12859-017-1630-z","article-title":"De novo assembly of highly polymorphic metagenomic data using in situ generated reference sequences and a novel BLAST-based assembly pipeline","volume":"18","author":"Lin","year":"2017","journal-title":"BMC Bioinf"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2019.10.003_bib21","first-page":"S87","article-title":"Efficacy and safety of ledipasvir\/sofosbuvir in 5052 Mongolian patients infected with hepatitis C virus genotype 1: real-life data from multi-center prospective cohort","volume":"13","author":"Baatarkhuu","year":"2019","journal-title":"Hepatol Int"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2019.10.003_bib22","first-page":"S159","article-title":"Outcome of HCV treatment using ledipasvir\/sofosbuvir combination in Mongolian population","volume":"11","author":"Nemekhbaatar","year":"2017","journal-title":"Hepatol Int"},{"issue":"Suppl 2","key":"10.1016\/j.jfma.2019.10.003_bib23","first-page":"S497","article-title":"Sofosbuvir and ledipasvir fixed-dose combination without ribavirin in treatment-naive patients with hepatitis C virus infection in Mongolia","volume":"12","author":"Naranzul","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2019.10.003_bib24","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.02524-15","article-title":"In\u00a0vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir","volume":"60","author":"Cheng","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jfma.2019.10.003_bib25","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00535-016-1290-1","article-title":"NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b","volume":"52","author":"Ogawa","year":"2017","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2019.10.003_bib26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/jvh.12850","article-title":"The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naive patients with chronic HCV genotype 1b infection in a real-world cohort","volume":"25","author":"Kozuka","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2019.10.003_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198642","article-title":"The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir","volume":"13","author":"Mawatari","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2019.10.003_bib28","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/jvh.12549","article-title":"Resistance analyses of Japanese hepatitis C-infected patients receiving sofosbuvir or ledipasvir\/sofosbuvir containing regimens in phase 3 studies","volume":"23","author":"Mizokami","year":"2016","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2019.10.003_bib29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jhep.2015.03.033","article-title":"Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A","volume":"63","author":"Akamatsu","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2019.10.003_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hep.28255","article-title":"Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3","volume":"63","author":"Peiffer","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2019.10.003_bib31","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s10517-016-3425-z","article-title":"Population polymorphism of IFNL3 and IFNL4 genes of type 3 interferon associated with spontaneous clearance of hepatitis C virus in representatives of Caucasian and Mongoloid races","volume":"161","author":"Malov","year":"2016","journal-title":"Bull Exp Biol Med"},{"key":"10.1016\/j.jfma.2019.10.003_bib32","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.4103\/0366-6999.166038","article-title":"Direct-acting antiviral agents resistance-associated polymorphisms in Chinese treatment-naive patients infected with genotype 1b hepatitis C virus","volume":"128","author":"Wang","year":"2015","journal-title":"Chin Med J"},{"key":"10.1016\/j.jfma.2019.10.003_bib33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/jmv.24608","article-title":"Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir\/asunaprevir","volume":"89","author":"Ikeda","year":"2017","journal-title":"J Med Virol"},{"key":"10.1016\/j.jfma.2019.10.003_bib34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jiz154","volume":"220","author":"Huang","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2019.10.003_bib35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jhep.2019.04.017","article-title":"Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: a systematic review and meta-analysis","volume":"71","author":"Ji","year":"2019","journal-title":"J Hepatol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664619308198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664619308198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:40:59Z","timestamp":1760539259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664619308198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0929664619308198"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2019.10.003","relation":{},"ISSN":["0929-6646"],"issn-type":[{"type":"print","value":"0929-6646"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance-associated substitution and ledipasvir\/sofosbuvir therapy in Mongolian chronic hepatitis C patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2019.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}